In the same meta-analysis, the prevalence of the G20210 A prothrombin gene pathologic variant among all patients and controls was 5.2% and 2.5%, respectively, and carriers were significantly more likely to develop CVT (OR 3.1, 95% CI 1.4–6.8) [26]. The gene discussed is F2; the disease is congenital vertical talus.